Vanda Pharmaceuticals Current Ratio 2006-2021 | VNDA

Vanda Pharmaceuticals current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Vanda Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.45B $0.07B 6.20
2021-03-31 $0.42B $0.06B 6.82
2020-12-31 $0.41B $0.07B 6.21
2020-09-30 $0.39B $0.06B 6.35
2020-06-30 $0.38B $0.06B 6.18
2020-03-31 $0.36B $0.06B 6.09
2019-12-31 $0.35B $0.06B 5.95
2019-09-30 $0.28B $0.06B 4.67
2019-06-30 $0.32B $0.06B 5.05
2019-03-31 $0.31B $0.06B 5.17
2018-12-31 $0.30B $0.05B 5.64
2018-09-30 $0.28B $0.05B 6.03
2018-06-30 $0.27B $0.05B 5.74
2018-03-31 $0.28B $0.07B 3.93
2017-12-31 $0.17B $0.07B 2.41
2017-09-30 $0.17B $0.07B 2.37
2017-06-30 $0.18B $0.08B 2.32
2017-03-31 $0.17B $0.07B 2.31
2016-12-31 $0.17B $0.05B 3.46
2016-09-30 $0.17B $0.05B 3.36
2016-06-30 $0.16B $0.05B 3.10
2016-03-31 $0.16B $0.06B 2.95
2015-12-31 $0.17B $0.05B 3.25
2015-09-30 $0.17B $0.05B 3.79
2015-06-30 $0.17B $0.05B 3.86
2015-03-31 $0.16B $0.03B 5.10
2014-12-31 $0.14B $0.01B 18.20
2014-09-30 $0.07B $0.04B 1.67
2014-06-30 $0.07B $0.04B 1.86
2014-03-31 $0.11B $0.05B 2.32
2013-12-31 $0.14B $0.03B 4.13
2013-09-30 $0.15B $0.03B 4.61
2013-06-30 $0.11B $0.03B 3.39
2013-03-31 $0.12B $0.03B 3.63
2012-12-31 $0.13B $0.03B 3.90
2012-09-30 $0.14B $0.04B 4.04
2012-06-30 $0.15B $0.03B 4.36
2012-03-31 $0.16B $0.03B 4.94
2011-12-31 $0.15B $0.03B 4.86
2011-09-30 $0.17B $0.03B 4.90
2011-06-30 $0.19B $0.03B 5.83
2011-03-31 $0.20B $0.03B 6.16
2010-12-31 $0.20B $0.03B 6.46
2010-09-30 $0.21B $0.03B 6.42
2010-06-30 $0.21B $0.04B 6.03
2010-03-31 $0.21B $0.04B 6.15
2009-12-31 $0.21B $0.03B 6.75
2009-09-30 $0.03B $0.01B 2.99
2009-06-30 $0.03B $0.01B 2.77
2009-03-31 $0.04B $0.00B 12.57
2008-12-31 $0.05B $0.00B 14.00
2008-09-30 $0.06B $0.00B 13.72
2008-06-30 $0.07B $0.01B 6.72
2008-03-31 $0.07B $0.01B 7.00
2007-12-31 $0.09B $0.01B 6.81
2007-09-30 $0.11B $0.02B 7.11
2007-06-30 $0.12B $0.01B 13.62
2007-03-31 $0.13B $0.01B 18.62
2006-12-31 $0.03B $0.01B 3.71
2006-09-30 $0.05B $0.01B 4.44
2006-06-30 $0.06B $0.02B 3.66
2006-03-31 $0.02B $0.01B 2.06
2005-12-31 $0.03B $0.01B 6.59
2005-09-30 $0.00B 0.00
2005-06-30 $0.00B 0.00
2005-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.001B $0.248B
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86